Cardio Diagnostics Holdings, Inc. (CDIO): A Bull Case Theory
We came across a bullish thesis on Cardio Diagnostics Holdings, Inc.(CDIO) on Stock Pursuit's Substack. In this article, we will summarize the bulls' thesis on CDIO. Cardio Diagnostics Holdings, Inc. (CDIO)'s share was trading at $4.4 as of 3rd June according to Yahoo Finance.
A biopharmaceutical research laboratory filled with scientists, illuminated by the glow of their equipment.
Cardio Diagnostics (CDIO), currently trading below net cash with no long-term debt and $8.7 million in cash against a market cap of just $6.9 million, emerged as a compelling deep value opportunity. While unprofitable, the company is not a typical pharma play—it operates in the epigenetic cardiovascular diagnostics space with clinically approved and already-commercialized tests. Its standout technology uses an AI-driven Integrated Genetic-Epigenetic Engine™ to assess risk for coronary heart disease and other conditions.
The flagship tests—Epi+Gen CHD and PrecisionCHD—demonstrate superior sensitivity compared to traditional tools and are the only ones of their kind globally. These tests, along with platforms like ACI and HeartRisk™, position Cardio Diagnostics in rapidly growing markets: the $8.5B coronary risk assessment space, the $24B cardiac biomarker market (9.4–14.1% CAGR), and the epigenetic diagnostics segment (15.5–19% CAGR). While recent quarterly revenue dropped sharply, full-year 2024 revenue doubled, and losses narrowed, aided by lower R&D spend and increased investment in sales personnel.
Recent partnerships with medical practices suggest this pivot toward sales execution is already in motion. Though institutional interest is limited, and analyst coverage unclear, the company's sub-net cash valuation, proven IP, and strategic positioning in preventative care make it a logical acquisition target—especially given precedent M&A activity in related diagnostics and genomics spaces. With a potential year of cash runway and peer-reviewed cost-savings data supporting commercial use, Cardio Diagnostics may offer asymmetric upside either through organic traction or a strategic buyout. For value-focused investors, it presents a low-risk, optionality-rich setup worth a small, speculative position.
We have covered a standout stock report of a on Fulcrum Therapeutics, Inc. (FULC) by the same author in May 2025. The article summarizes the bulls' thesis on FULC on Stock Pursuit's Substack. Fulcrum Therapeutics (FULC) recently surged over 110% from around $3.30 to $7.00, reflecting growing optimism but also presenting a prime opportunity to take profits.
Cardio Diagnostics Holdings, Inc. (CDIO) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 2 hedge fund portfolios held CDIO at the end of the first quarter which was 4 in the previous quarter. While we acknowledge the risk and potential of CDIO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article was originally published at Insider Monkey.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
Châtillon, France, June 11, 2025 DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the 'Company'), held its Combined General Meeting (the 'General Meeting'). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company's shareholders approved all resolutions submitted by the Board of Directors. The resolutions and the voting results are posted on the Investors/Annual General Meetings section of the Company's website: About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual's underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin's immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company's food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age). DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309). For more information, please visit and engage with us on X (formerly Twitter) and LinkedIn. Viaskin and EPIT are trademarks of DBV Technologies. Investor Contact Katie MatthewsDBV Media ContactAngela Marcucci DBV Attachment PDF VersionFehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
an hour ago
- Yahoo
01 Communique Engages Oak Hill
Toronto, Ontario--(Newsfile Corp. - June 11, 2025) - 01 Communique Laboratory Inc. (TSXV: ONE) (OTC Pink: OONEF) (the "Company"), one of the first-to-market, enterprise level cybersecurity providers for the quantum computing era, is pleased to announce that it has retained the services of Oak Hill Financial Inc. ("Oak Hill") to provide, among other things, investor relations, business and capital markets advisory services to the Company (the "Services"). Oak Hill is a Toronto-based investor relations and capital markets advisory firm that has been engaged to, among other things, heighten market and brand awareness for the Company as well as to broaden the awareness of the Company within the investment community via email and phone campaigns. The agreement with Oak Hill is effective as of June 10, 2025 and has an initial period of two months. The agreement is subject to TSX Venture Exchange approval. Oak Hill has agreed to comply with all applicable securities laws and policies of the TSX Venture Exchange in providing its Services. In connection with the Services, Oak Hill will be paid a monthly fee of $12,000, plus applicable taxes. Neither Oak Hill nor its principals have any interest, directly or indirectly, in the Corporation or its securities, or any right or intent to acquire such an interest. About 01 Communique Established in 1992, 01 Communique (TSXV: ONE) (OTC Pink: OONEF) has always been at the forefront of technology. The Company's cyber security business unit focuses on post-quantum cybersecurity with the development of its IronCAP™ product line. IronCAP™'s technologies are patent-protected in the U.S.A. by its patents #11,271,715 and #11,669,833. The Company's remote access business unit provides its customers with a suite of secure remote access services and products under its I'm InTouch and I'm OnCall product offerings. The remote access offerings are protected in the U.S.A. by its patents #6,928,479 / #6,938,076 / #8,234,701; in Canada by its patents #2,309,398 / #2,524,039 and in Japan by its patent #4,875,094. For more information, visit the Company's web site at and Neither TSX Venture Exchange ("TSX-V") nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. INVESTOR CONTACT:Brian StringerChief Financial Officer01 Communique(905) 795-2888 To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
C Spire Named 2025 Southeast Partner of the Year by Arctic Wolf
Ridgeland-based Business Receives Honor from Global Leader in Security Operations RIDGELAND, Miss., June 11, 2025--(BUSINESS WIRE)--C Spire has been named Arctic Wolf Southeast Partner of the Year for 2025. This recognition highlights the company's exceptional leadership in cybersecurity, outstanding service delivery, and commitment to helping mutual customers drive innovation and achieve stronger security outcomes. "We are honored to be recognized as Arctic Wolf Southeast Partner of the Year and look forward to delivering even more cybersecurity innovation and value for our customers," said Drake Cushing, Senior Vice President and General Manager for C Spire Business. "Cybersecurity threats and their constant advancement in attack methods continue to grow and require forward-focusing technology to protect businesses. Through our partnership with Arctic Wolf, C Spire continues to deliver advanced technology our customers need and expect from us." The Arctic Wolf Partner of the Year Awards recognize elite partners who have demonstrated outstanding leadership in helping organizations improve their security operations through Arctic Wolf's portfolio of solutions. Now in their eighth year, the honors celebrate top-performing companies that have shown excellence in security practice, executive alignment, revenue growth, and service. "This year's award winners represent the very best of the Arctic Wolf partner community," said Will Briggs, Senior Vice President, Global Channels, Arctic Wolf. "Each of these organizations has demonstrated exceptional commitment to our shared mission to end cyber risk, helping customers navigate an increasingly complex threat landscape with confidence and resilience. We're proud to recognize their achievements and celebrate the critical role they play in driving meaningful security outcomes." C Spire Business is a division of C Spire, a diversified telecommunications and technology services provider. C Spire has highly certified IT engineering talent in markets across the Southeast U.S. and specializes in connecting businesses of all sizes with best-in-class solutions. Cloud, collaboration, cybersecurity, managed IT, fiber connectivity — C Spire Business delivers all the power and expertise organizations need to win. As organizations worldwide face an increasingly complex threat landscape and a persistent cybersecurity talent shortage, over 10,000 organizations globally now rely on the Arctic Wolf Aurora Platform to help end cyber risk. Built on an open-XDR architecture and powered by Alpha AI™ technologies, the Aurora Platform is designed to deliver positive security outcomes at scale. Each week, it ingests, parses, enriches, and analyzes over eight trillion security events—transforming overwhelming volumes of data into an average of just one actionable alert per customer per day. Additional Resources For more information about C Spire, visit For more information about Arctic Wolf, please visit About C SpireC Spire is a diversified telecommunications and technology services company that provides a full suite of dedicated internet, wireless, IP Voice, data, cloud and managed IT services for businesses and enterprises, world-class, customer-inspired wireless communications, as well as fiber internet for consumers. This news release and other announcements are available at For more information about C Spire, visit or follow us on Facebook at or X at View source version on Contacts Press Contact C SpireCourtney Grimes, 601-746-2737cgrimes@